LA JOLLA, Calif. – Feb. 2, 2017 – Today marks the annual Rheumatoid Arthritis Awareness Day, which was created to improve the nation’s understanding of Rheumatoid Arthritis (“RA”) so that those suffering with the disease can get information on the best care and treatments available. Rheumatoid Arthritis is caused by the immune system attacking the lining of the joints, causing great pain and inflammation for people living with it. According to the Rheumatoid Patient Foundation, one third of RA patients do not respond to the traditional standard of care medications. There is no cure for RA, but StemGenex Medical Group is proud to be advocating for patients with unmet clinical needs and providing new hope for optimum health and better quality of life through arthritis stem cell therapy.
“I have lived with Rheumatoid Arthritis for nearly 35 years and this day serves as an important reminder of the challenges people living with RA face every day,” says Rita Alexander, Chief Administrative Officer of StemGenex Medical Group. “Their strength and determination are what motivates us as a company to help those suffering with the disease better understand available treatment options and empower them to take control of their personal health.”
In December 2016, the 21st Century Cures Act, a landmark piece of healthcare legislation was signed into law after receiving overwhelming bipartisan support. The law is designed to accelerate the availability of new medical treatments to patients suffering with debilitating diseases by speeding up the Federal Drug Administration’s (“FDA”) approval processes. The act aims to inspire innovation and discovery in medicine by improving patient access to safe and efficacious treatments, such as stem cell therapies.
“This groundbreaking legislation provides those suffering with incurable diseases, such as Rheumatoid Arthritis to have more treatment options when their clinical needs remain unmet with standard medicines and treatments, says Rita Alexander. “We are proud to support this progressive healthcare movement and provide awareness, which is crucial to patients living with diseases for which there are currently limited treatments options available.”
About StemGenex Medical Group
StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides access to stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment, StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health (“NIH”) for Multiple Sclerosis, Parkinson’s Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (“COPD”) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.
Read more about the Rheumatoid Arthritis Stem Cell Therapy we offer at StemGenex!
For more information, visit www.stem-genex.org, or contact Jamie Schubert, Director of Media and Community Relations, [email protected], 800-609-7795
]]>
LA JOLLA – November 29, 2016 – StemGenex recently submitted comments to the Food and Drug Administration (FDA) docket on the future regulation of adult adipose-derived stem cell treatments, “Draft Guidances Relating to the Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.”
StemGenex is dedicated to ensuring that people with unmet clinical needs have access to safe and effective stem cell treatment. We believe that a collaboration between the FDA and existing accrediting organizations can result in a regulatory pathway that ensures patient safety while simultaneously accelerating access to stem cell treatment for patients.
Dr. Steven A. Brody, Chief Scientific Officer of StemGenex said, “the FDA’s future regulation of stem cell treatments is a topic of considerable interest throughout the U.S.”
“The future regulatory pathway for stem cell therapies is vital for patients who feel they have run out of options, said Dr. Brody. “There are many different opinions regarding the regulation of stem cells and we hope the recent public hearing and thousands of submissions to the FDA docket will demonstrate the overwhelming demand for access to life-altering stem cell treatments.”
The FDA’s current Guidances relating to HCT/P’s (Human Cells, Tissues or Cellular or Tissue-Based Products) propose that adipose-derived stem cells from a patient be regulated in the same manner as a manufactured drug. The approval process for a new drug can take 10 to 15 years and cost a minimum of tens of millions of dollars. If the Guidances are finalized as they are currently written it will delay access to stem cell therapies in the United States and cause many Americans who are struggling with degenerative disease to seek treatment outside of the country.
StemGenex proposes that adult adipose-derived stem cell therapies be regulated within the same comprehensive standards of organizations such as the American Association of Blood Banks (AABB). The AABB standards are recognized nationally and internationally and are based on the core principals of quality, scientific research and patient safety. Organizations such as the AABB have successfully set standards for the safe use of blood and tissue products for over 20 years. Ideally, the high standards of accrediting organizations such as the AABB are suited to guide and monitor the safe use of adipose-derived stem cells.
StemGenex is also in support of stem cell research, treatment providers, and clinics being required to be registered on a National Directory. The development, participation and designated requirements of such a clinical registry would provide a reasonable alternative to regulating adult adipose-derived stem cell treatment as a drug.
“Stem cell therapies are one of the most promising areas for the next generation of treatments,” said Chief Administrative Officer Rita Alexander. “The availability of these therapies is imperative for people battling these devastating diseases.”
If you or someone you know is interested stem cell treatment, visit www.stem-genex.org, or call (855) 742-STEM to speak with a Patient Advocate.
]]>Stem cells for MS are offering hope to many with debilitating conditions, including to Calumet residents who hope to benefit from new therapies using their own cells.
Mike Bausano suffered a stroke on Aug. 1 due to dislodged plaque that traveled to his brain, after Marquette doctors placed stints in his arteries to treat the heart attack he had on July 31.
“Neurons can’t live without oxygen too long,” Bausano said.. “A big chunk of my brain died.”
Mike Bausano suffered a stroke on Aug. 1 which killed the neurons in a large portion of his brain and reduced his mobility. He is currently undergoing stem cell treatment to regain control over the left side of his body.
When he went home from the hospital Aug. 27, he had no control over the left side of his body, but can walk with a walker or holding on to someone after extensive physical therapy. He also did eye exercises to overcome left neglect caused by optic nerve damage.
Able to see his computer again, Bausano found Stem Genex and headed to La Jolla, California for an Aug. 4 treatment costing $15,000.
The procedure involved using stem cells harvested from belly fat that are irradiated before being returned to Bausano’s left arm, leg, lumbar region and in his nasal cavity, close to his brain.
Ideally, the stem cells will repair damaged nerve endings within six to 12 months.
“Be patient,” Bausano tells himself. “I’m optimistic (but) It takes a long time for the body to repair itself. It’s a little unnerving. I want to see results.”
So does Laura Erkkila,who’s has had multiple sclerosis for 22 years, the last 12 of which she’s spent in a wheelchair. She’s planning to head to Mexico to have stem cells harvested from her bone marrow which will be replaced after she undergoes chemotherapy to eradicate the MS from her body. The 28-day procedure is the only treatment that has shown promising results for eradicating MS. Whether or not it restores damages wrought by the disease remains to be seen.
“I won’t get any worse,” Erkkila said, hopeful about her condition for the first time. “Actually the disease will be gone. I won’t have MS anymore. It’s a phenomenal treatment.
“If you get it early enough, it could be a cure,” she said.
Erkkila will no longer have to take expensive MS drugs – one of which costs $7,000 per month. Her health insurance covered that expense, but won’t cover $55,000 procedure.
Visit Erkkila’s Go Fund Me page if you can donate to help her cover expenses. Or attend a roast beef fundraising dinner from 4 to 7 p.m. Oct. 15 at Millers Recreation, featuring a 50/50 raffle, bake sale and raffle with prizes including a handmade quilt and Packer tickets.
Stem cells, the body’s “master cells,” are the precursor cells that develop into blood, brain, bones and organs, according to the Food and Drug Administration. Stem cell research for MS is growing, but their promise in medicine is potentially to repair, restore, replace and regenerate cells that could then be used to treat many medical conditions and diseases, some more effectively than others.
FDA cautions consumers to make sure it’s approved the stem cell treatment under consideration or that it is being studied under a clinical investigation that has been submitted to and allowed to proceed by FDA.
This is a republication of the article, “Stem Cell Therapy Helps Local Stroke, MS Patients,” originally published on 10/6/2016 by The Daily Mining Gazette which can be read here.
“After being on the phone for hours and having all my questions answered by StemGenex about stem cell treatment for Multiple Sclerosis, I booked an appointment. I had stem cell therapy on September 13, 2016 at Stemgenex. I have energy again!”
“My typical day before the treatment included waking up in the morning after about ten hours of sleep. I felt like I hadn’t slept in days. I’d go to work, come home, take a nap (at least two hours), and then try to make dinner. Forget about the laundry and cleaning the house, who had energy for that? Not Me! I would get horrible muscle spasms in my shoulders and my muscles would get so tight which caused horrible headaches. I felt like I was living in a fog.”
“Today, I wake up feeling refreshed! I go to work, come home, start dinner, do some laundry, do some cleaning, realizing how much everything has been neglected. I can actually stay up late and function the next morning! My husband said to me the other day that “my best friend is back” which was music to my ears. I have not had any muscle spasms in my shoulders. I actually feel like I’m living again! I still have numbness in my hands, but it has only been 3 weeks. If I have had this much improvement in three weeks, I can’t wait to see what 3, 6, 9 months will be like. The joke in the family is now that they all have to learn how to keep up with me! I had a lady recently tell me, “boy you sure walk fast.” This treatment is real. StemGenex Medical Group uses your own stem cells, and no chemotherapy! I’m a believer and I hope that I have made you a believer as well. Thank you StemGenex for giving my life back!” – Karin B.
This testimonial includes a description of this patient’s actual results. These results may not be typical or expected for the particular disease type described in this testimonial. You should not expect to experience these results. Stem cell therapy is not FDA approved and is not a cure for any medical condition. ]]>
Among the different therapeutic approaches being explored for treating MS, adult stem cell therapy continues to be one of the most discussed and anticipated in the MS community. “Stem cells” — the common term for undifferentiated, self-renewing proliferating cells — are currently being investigated for their ability to treat patients in a wide range of disease indications, including Multiple Sclerosis, due to their ability to reboot the immune system, address inflammation in the body and repair damage caused by injury or disease. For MS, some researchers believe that stem cell therapy can effectively repair damaged myelin, preventing the progression of the disease and minimizing its effect on patients’ quality of life.
Stem cell treatment for Multiple Sclerosis begins with the introduction of adult mesenchymal stem cells (MSC) taken from the Stromal Vascular Fraction (SVF) — the fatty material that is removed in procedures such as lipsosuction — which is processed and reintroduced back into the body. From there, these MSCs are believed to be able to travel past the blood brain barrier and repair the myelin sheath around nerve cells that becomes damaged by the immune system in MS in a process known as “remyelination.” In addition, stem cells also act as modulators of the immune system in patients with multiple sclerosis, as MSCs secrete cytokines and other molecules that can have an anti-inflammatory effect or produce an inhibitory action on pro-inflammatory pathways. Since MS is an autoimmune disease, if stem cell therapy is proven to restore normal function to the immune system as well as repair damaged myelin, it would represent a revolutionary, next generation approach to treating the disease.
Clinical Studies Testing Stem Cell Therapy For MS
While stem cell therapy is currently available to patients seeking therapeutic alternatives for treating MS where traditional prescribed therapies have failed, MS stem cell research is still being studied, particularly with respect to how effective the therapy is in improving quality of life for patients, and how to best deliver stem cells back into the body. StemGenex, a company that is committed to advancing stem cell therapy for a wide range of disease, is currently sponsoring several clinical studies one of which is for the treatment of Multiple Sclerosis. “Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis” aims to recruit 100 patients between the ages of 18 and 65 years old to particulate in the MS clinical study. Recruited participants will be treated with a stem cell concentrate derived from their own adult adipose (fat) tissue, or the stromal vascular fraction (SVF).
Are you interested in participating in the Multiple Sclerosis Stem Cell Clinical Study? Call (855) 742-7836 to speak with a Patient Advocate.
Researching clinicians administer a customized treatment that may include: intravenous drip, intra nasal administration or targeted direct administrations. The locations in the body receiving the cells are the areas in most need of immunomodulatory stem cells to help repair damage. When the cells are in the patient’s body, they disperse into adjacent tissue, differentiate into mature cells of the surrounding tissue, secrete immunomodulatory growth factors, and/or attract blood vessel growth. In the case of MS, stem cells’ ability to differentiate into mature cells that may repair myelin as well as stabilize the immune system is what researchers believe can positively impact quality of life for patients as well as slow down disease progression.
For the present clinical studies, to determine if there is a benefit to receiving a “dose” of SVF, research clinicians will monitor patients for a variety of outcome measures. Primarily, StemGenex is interested in observing a change in overall quality of life over a twelve-month period following treatment at baseline. During this twelve-month period, patients will be assessed for quality of life changes at times of one, three, six, and twelve months following treatment using the Multiple Sclerosis Quality of Life Inventory (MSQLI). According to the National Multiple Sclerosis Society, this inventory is composed of ten separate rating scales that assess everything from feelings of fatigue to sexual satisfaction and can be completed entirely by the patient in approximately 30-45 minutes. The change in score from each individual rating scale during the twelve-month period is a separate secondary outcome measure in the study.
The Need For MS Clinical Study Participation
In spite of recent therapeutic advancements, there are still major unmet medical needs for those with Multiple Sclerosis. While improved disease modifying drugs continue to delay the progression of the relapsing forms of the disease, most patients continue to suffer from worsening symptoms, and can eventually develop secondary progressive MS, for which there are no FDA approved therapies. In many cases, MS patients have few if any options when it comes to conventional therapy, making the exploration of alternative treatment options such as stem cell therapy critically important to helping those living with the disease.
Stem Cell therapy is a different approach from taking a prescribed medicine — its success depends on patients’ willingness to try the therapy themselves and allow investigators to optimize it for the best results possible. Those who participate are given early access to a treatment that could potentially improve their condition. In addition, their participation makes it possible for researchers to accelerate development of novel therapies. In this way, the future of stem cell therapy for Multiple Sclerosis and whether it is fully developed into a mainstream treatment option for those with MS depends upon clinical studies that confirm its effectiveness.
If you are interested in participating in the Multiple Sclerosis Stem Cell Clinical Study “Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis” call (855) 742-7836 to speak with a Patient Advocate today!
]]>
“My name is Newt and approximately 20 years ago, I asked my doctor about the shaking in my right hand. He said he didn’t want to alarm me, but this could be the beginning of Parkinson’s Disease. About five to six years ago, the shaking was getting notably worse and I was referred to a neurologist. At that time, he prescribed me medications.”
“A friend of my sister had stem cell treatment with some improvement. I researched stem cell treatments, and StemGenex was recommended by this friend, so I decided to go ahead with the procedure.”
“On June 5, 2015, I received a stem cell treatment for Parkinson’s Disease. The treatment was provided by StemGenex in California.”
“Since that time, I have noticed improvement in my ability to control the shakes in my right hand. In January 2016, I was able to thread a needle twice and sew on some buttons, which is something I could not do before the treatment. I also have been able to reach above my head to put tools on peg board hooks in my shop. Now, there are times I am able to control the shakes.”
“In August 2016, I was able to trim tall hedges and paint windows frames on my house. For almost a year, I have been able to make lamps by turning wood on my lathe. Since March, I have also been taking dance lessons. I have been able to prepare and freeze peaches. I made a peach pie and have been playing golf. I live alone, which I am not sure would be possible without the stem cell treatment.”
“There are so many incurable diseases for which treatment options are very limited. Some diseases are treated with drugs with known and unknown serious side effects. With stem cell treatment, which means using my own stem cells, there is little or no risk of rejection, and it is safe.”
“Where would I be now without stem cell treatment? I probably would not be living alone, and I don’t think I would be able to travel across the county like I did recently.”
This testimonial includes a description of this patient’s actual results. These results may not be typical or expected for the particular disease type described in this testimonial. You should not expect to experience these results. Stem cell therapy is not FDA approved and is not a cure for any medical condition. ]]>
The FDA is currently in the process of finalizing a regulatory pathway for stem cell therapies. With less than one day before the FDA docket closes, we urge you to share your personal experience with stem cell therapy and submit comments on the FDA docket to support continued access of accessible, safe and effective stem cell regulation treatment options available in the United States through trusted Medical Professionals.
Click here to Submit comments on the FDA Docket
*FDA Docket closes at 11:59pm EST on Tuesday, September 27, 2016.
The current framework applicable to stem cell therapy and the use of a person’s own stem cells is based on the same regulatory pathway used for chemical drugs, vaccines and biologics. As a result, stem cells transplanted back into the same patient are included in the broader statutory definition of drugs. The regulatory pathway to market a new drug is a very long process, which under the best circumstances can take 10 to 15 years at a cost of tens of millions of dollars. If the FDA chooses to regulate a person’s own stem cells as a drug, future access to stem cell therapy in the U.S. may be limited and possibly obsolete for those with unmet clinical needs.
Dr. Steven A. Brody, Chief Scientific Officer at StemGenex recently presented at the FDA Public Hearing on Draft Guidances Relating to the Regulation of HCT/Ps. The purpose of the hearing was to obtain comments on four draft guidances relating to the future regulation of adult stem cell therapies. The event was heavily attended by nearly 500 attendees and 90 speakers, whereas many of the speakers advocated for continued access to safe and effective adult stem cell therapies.
Amending the draft guidances would be a positive step towards providing medical professionals the ability to offer their patients stem cell therapy, a treatment option that has shown life-changing quality of life benefits for countless individuals.
Stem cell therapies hold incredible potential for the future of health care in the United States and around the world. We hope you will join us and participate in this critical journey and share your story and comments about stem cell therapy with the FDA.
]]>
LA JOLLA – September 20, 2016 – “Stem cells have arrived and have captivated the scientific and medical communities. With this excitement comes responsibility and with this responsibility comes regulation,” said the Chief Scientific Officer of StemGenex, Steven A. Brody, M.D., Ph.D., in his presentation to the Food and Drug Administration (FDA) at the Public Hearing held on September 12 and 13, 2016, at the National Institutes of Health (NIH) located in Bethesda, MD.
The purpose of the public hearing was to obtain comments on four Draft Guidances of Human Cells, Tissues and Cellular and Tissue-Based Products relating to the regulation of adult stem cell therapies. The event was heavily attended by nearly 500 attendees and 90 speakers which included national health care professionals, researchers, accrediting organizations, and patients. Representatives of StemGenex were overwhelmed by the heartfelt testimonials from patients who have had their lives changed by adipose-derived stem cell treatments.
A majority of the speakers advocated for continued access to safe and effective adult stem cell therapies. Others advocated for adult stem cells to be regulated as a drug, which could potentially delay patient access to life-changing therapies. The regulatory pathway to market a new drug is a very long process, which under the best circumstances can take 10 to 15 years at a cost of tens of millions of dollars.
In his presentation, Dr. Brody asked the FDA to consider the following changes as they finalize the guidances:
- Recognize the structural and non-structural properties of adipose tissue.
- Review and expand the definition of minimal manipulation.
- Regulate human cells, tissues and cellular and tissue-based products in the same manner as blood tissue products within the existing comprehensive standards of organizations such as the American Association of Blood Banks (AABB).
“Organizations such as the AABB are ideally suited to safely guide and regulate the use of adipose-derived stem cells,” said Dr. Brody. “The AABB established regulatory framework would require stem cell treatment centers to meet standards that would ensure public safety.”
Amending the draft guidances as related to the above recommendations would be a positive step towards providing medical professionals with the ability to offer their patients an option where there is little hope for unmet clinical needs.
“StemGenex will tirelessly advocate for stem cell treatment and access to the healing benefits of their own cells,” said Chief Administrative Officer Rita Alexander. “We believe that stem cells are key to advancing the future of medicine.”
If you or someone you know is interested stem cell treatment, visit www.stem-genex.org, or call (855) 742-STEM to speak with a Patient Advocate.
]]>
LA JOLLA – September 8, 2016 – StemGenex, a world leader offering access to autologous adipose-derived stem cell treatment, recently announced it has named Steven A. Brody, M.D., Ph.D. as Chief Scientific Officer. Dr. Brody is an internationally recognized physician-scientist specializing in regenerative and restorative medicine, bioidentical hormone therapy, and genomic methods to enhance health. “We are enthusiastic about collaborating with Dr. Brody because of his wide range of research and clinical administration of scientific advancements that will change the future of medicine as we know it,” said Dr. Andre Lallande, Medical Director. “His lifelong commitment to developments in reproductive medicine and laboratory innovations make him an excellent choice for Chief Scientific Officer.” In this new role, Dr. Brody will research the scientific basis of clinical procedures and laboratory techniques, objectively analyze clinical outcomes and lead compliance and regulatory initiatives. “Stem cell therapy is the future of medicine. It has the potential to both repair and regenerate damaged tissues and organs,” said Dr. Brody. “Clinical research and growth is vital in providing the highest quality and most effective therapy for patients.” Among its science and research initiatives, StemGenex sponsors five clinical studies registered with the National Institutes of Health for Multiple Sclerosis, Parkinson’s Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to evaluate the quality of life changes in individuals following adipose-derived stem cell treatment. Each clinical study has been approved by an independent institutional review board to ensure proper oversight and protocols are being followed. “We consider clinical research a core competency and a significant advantage compared with adult adipose stem cell therapy and treatment centers offering unregistered studies,” said Dr. Lallande. Prior to joining StemGenex, Dr. Brody was Medical Director of Lifespan Medical Institute in La Jolla. He previously held positions of Director of Reproductive Endocrinology at Alvarado Hospital in San Diego Dr. Brody received his medical degree from Washington U. School of Medicine and has trained at Yale-New Haven Hospital, the National Institutes of Health, Stanford University School of Medicine and Baylor College of Medicine. 
A prolific researcher, Dr. Brody has authored a number of influential articles and has written two medical textbooks. He partnered with the 2010 Nobel Prize recipient in Medicine, Dr. Robert G. Edwards, to co-author the textbook, “Principals and Practice of Assisted Human Reproduction.” In recognition of his work, he was chosen San Diego’s “Doctor of the Year” by the San Diego Medical Journal and Metropolitan Magazine.
# # #
About StemGenex StemGenex is committed to helping people with unmet clinical needs achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides access to stem cell researchers and therapy options to help individuals suffering with inflammatory and degenerative illnesses. Board Certified Physicians administer safe and effective adult adipose-derived stem cell therapy, a minimally invasive procedure using an individual’s own stem cells to treat diseases including Multiple Sclerosis, Parkinson’s Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis.
]]>“Stem Cell Therapy Gave me Back my Life!” Steve’s Parkinson’s Success Story with StemGenex Medical Group
Stem cells have the ability to heal and have been shown to slow the progression of an outstanding variety of conditions, ranging from injures to chronic debilitating diseases.
Steve, a very energetic and active Albuquerque native, was diagnosed with Parkinson’s Disease in 2013. Due to the debilitating disease, Steve was becoming depressed, losing hope and preparing to retire from his job because he was so exhausted each day. Seeing no way out, Steve’s wife urged him to look into stem cell therapy as a treatment option for Parkinson’s Disease.
StemGenex Medical Group Welcome Center
Making sure he chose the treatment center with the highest stem cell treatment standardsand patient quality care, Steve spent countless hours researching stem cell treatment centers throughout the world. Steve chose StemGenex Medical Group, one of the largest stem cell treatment centers on the west coast and a well-known industry leader in providing safe and effective stem cell treatment.
“Stem cell treatment gave me back my life! The first thing I noticed after stem cell therapy was that I could smell again and food tasted good again. I am no longer exhausted and now jump out of bed to go to work each day. My mobility and balance is better. I got back on the treadmill and I started lifting weights again, which I couldn’t do before stem cell treatment. I’ve progressed now to where I was almost four years ago!” says Steve.
“I went to go see my doctor shortly after stem cell treatment at StemGenex Medical Group and he was impressed! After having stem cell treatment, you see the light at the end of the tunnel. Stem cell treatment has changed my life!” says Steve.
StemGenex Medical Group Medical & Clinical Staff
“StemGenex Medical Group was the only stem cell treatment center who could answer all of my questions and they offered a Parkinson’s stem cell research clinical study registered through the National Institutes of Health (NIH). The staff is excellent, very friendly, kind and sympathetic. They were all very genuine people,” says Steve.
The demonstrated benefits of adult stem cell therapy are well-documented by clinicians and researchers. StemGenex Medical Group has collected anecdotal feedback based upon direct reports from patients which has shown symptoms to have dramatically improved and quality of life has substantially increased.
StemGenex Medical Group’s principal purpose is to help people with unmet clinical needs achieve optimum health and better quality of life including the use of adipose-derived stem cell therapy and provides each patient a customized integrative health recovery program. StemGenex sponsors five NIH-registered clinical studies which have been established to evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.
This testimonial includes a description of this patient’s actual results. These results may not be typical or expected for the particular disease type described in this testimonial. You should not expect to experience these results. Stem cell therapy is not FDA approved and is not a cure for any medical condition. ]]>